Multisource drug policies in Latin America: Survey of 10 countries

Bulletin of the World Health Organization

Volumn 83, Issue 1, 2005, Pages 64-70

  Homedes, Núria ^a   Ugalde, Antonio ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Drug and narcotic control; Drugs, Generic classification legislation; Latin America; Legislation, Drug; Therapeutic equivalency

Indexed keywords

DRUG; GENERIC DRUG;

DISEASE TREATMENT; DRUG PRESCRIBING; HEALTH POLICY; LEGISLATION;

ARGENTINA; BIOEQUIVALENCE; BOLIVIA; BRAZIL; CHILE; CLASSIFICATION; COLOMBIA; COST; COSTA RICA; DRUG LEGISLATION; ECUADOR; NICARAGUA; PERU; POLICY; QUESTIONNAIRE; REGISTRATION; REVIEW; SOUTH AND CENTRAL AMERICA; URUGUAY;

DATA COLLECTION; DRUG AND NARCOTIC CONTROL; DRUGS, GENERIC; GOVERNMENT AGENCIES; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LATIN AMERICA; LEGISLATION, DRUG; TERMINOLOGY; THERAPEUTIC EQUIVALENCY;

LATIN AMERICA; WESTERN HEMISPHERE; WORLD;

EID: 12444347368     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Kremer M. Pharmaceutical in the developing world. Journal of Economic Perspectives 2002;16:67-90.
2. Cortez R. Desarrollo de una estrategia social para Perú [Development of a social strategy for Peru]. Lima: BID-Centro de Investigación de la Universidad del Pacífico; 2001. In Spanish.
3. Gonzalez GG. Las vidas que no tienen remedios [Humans without medicines]. Buenos Aires: El Clarín; 2001. In Spanish.
4. World Health Organization. WHO medicines strategy: framework for action in essential drugs and medicines policy 2000-2003. Geneva: WHO; 2000.
5. Bapna JS, Tripathi CD, Tekur U. Drug utilization patterns in the Third World. Pharmacoeconomics 1996;9:286-94.
6. Vargas Giron M. Acceso y uso racional de medicamentos en el Peru [Access and rational use of drugs in Peru). In: Arroyo J, editor. La salud peruana en el siglo XXI. Retos y propuestas de politica [Health conditions in Peru in the XXI Century. Challeges and policy proposals). Lima: CIES, DFID; 2002. In Spanish.
7. World Health Organization. The public and the private circuits for the distribution of drugs in the Chilean system: WHO Action Programme for Essential Drugs. Geneva: WHO; 1999.
8. World Health Organization. How to develop and implement a national drug policy. Geneva: WHO; 2001.
9. World Health Organization. Progress of WHO Member States in developing national drug policies and in revising essential drug lists. Geneva: WHO; 1998. WHO document WHO/DAP/98.7.
10. World Health Organization. Guidelines for developing national drug policies. Geneva: WHO; 1988.
11. World Health Organization. Essential Drugs and Medicines Policy: glossary, 2004. Available from: http://www.who.int/medicines/library/qsm/manual- on-marketing/multisource-gloss.html
12. ANMAT. La ANMAT y la bioequivalencia. [ANMAT and bioequivalence]. ANMAT Informa 2002;10:33-64. In Spanish.
13. Agenda Nacional de Vigilância Sanitaria (ANVISA), Ministério de Saúde. Medicamentos genéricos en Brasil. Aspectos regulatorios [Generic medicines in Brazil. Regulatory aspects]. Brasilia: ANVISA; 2002. In Portuguese.
14. Secretaria de Salud de México. Genéricos intercambiables [Interchangeable generics], 2003 (http://www.ssa.gob.mx), In Spanish.
15. Chile, Ministerio de Salud. Reglamento del sistema nacional de control de productos farmacéuticos, alimentos de uso médico y cosméticos. [Rules of the national system to control pharmaceutical products, therapeutic supplements and cosmetics]. Santiago: Ministerio de Salud; 1995 (D.S. 1876/1995).
16. Kaplan WA, Laing R. Paying for pharmaceutical registration in developing countries. Health Policy and Planning 2003;18:237-48.
17. República de Argentina, Ministerio de Salud. Política para la utilización de medicamentos por su nombre genérico. Una herramienta para el acceso a la salud [A policy for the use of medicines by their generic name. A tool to improve access to health care]. Buenos Aires: Ministerio de Salud; May 2002. In Spanish.
18. Tobar F, Godoy Garraza L. Utilización del nombre genérico de los medicamentos [The utilization of generic names]. Buenos Aires: Ministerio de Salud Pública, Comisión Nacional de Programas de Investigación Sanitaria; 2003. In Spanish.
19. Ugalde A, Cañas M. Últimos intentos para frustar la aprobación de la Ley de Genéricos en Argentina [Last attempts to stop the passing of the Generic Law in Argentina]. Boletín Fármacos 2002;5:18-22. In Spanish. (Also available at www.boletinfarmacos.org)
20. Stolley PD, Laporte JR. The public health, the university and pharamcoepidemiology. In: Strom BL, editor. Pharmacoepidemiology. Indianapolis (IN): John Wiley and Sons; 2000. p. 75-89.
21. Figueres A, Vazquez S, Arnau JM, Laporte JR. Health needs, drug registration and control in less developed countries - the Peruvian case. Pharmacoepidemiology and Drug Safety 2002;11:63-4.